Sobrevida a 1 y a 5 años en pacientes con hipertensión pulmonar del grupo 1 atendidos en un centro de alta complejidad en Bogotá

Barón Castro, Oscar Ricardo; Conde Camacho, Rafael Enrique; Bastidas Goyes, Alirio Rodrigo; Mora Barrero, Angelica Vanessa; Tuta Quintero,Eduardo Andrés

dc.contributor.author	Barón Castro, Oscar Ricardo
dc.contributor.author	Conde Camacho, Rafael Enrique
dc.contributor.author	Bastidas Goyes, Alirio Rodrigo
dc.contributor.author	Mora Barrero, Angelica Vanessa
dc.contributor.author	Tuta Quintero,Eduardo Andrés
dc.date.accessioned	2024-06-28T11:35:04Z
dc.date.available	2024-06-28T11:35:04Z
dc.date.issued	2024-01-29
dc.identifier.uri	http://hdl.handle.net/10818/60704
dc.description	21 páginas	es_CO
dc.description.abstract	La sobrevida de pacientes con hipertensión arterial pulmonar (HAP) no está descrita en población a gran altura (≥ 2.500 ms.n.m), ni tampoco las características clínicas, funcionales y hemodinámicas que determinan el riesgo de mortalidad.	es_CO
dc.format	application/pdf	es_CO
dc.language.iso	spa	es_CO
dc.publisher	Universidad de La Sabana	es_CO
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject.other	Hipertensión arterial pulmonar
dc.subject.other	sobrevida
dc.subject.other	Gran altitud
dc.title	Sobrevida a 1 y a 5 años en pacientes con hipertensión pulmonar del grupo 1 atendidos en un centro de alta complejidad en Bogotá	es_CO
dc.type	bachelor thesis	es_CO
dc.type.hasVersion	publishedVersion	es_CO
dc.rights.accessRights	restrictedAccess	es_CO
dcterms.references	Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug;142(2):448-456. doi: 10.1378/chest.11-1460. PMID: 22281797.
dcterms.references	Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-223.
dcterms.references	Marc Humbert, Gabor Kovacs, Marius M Hoeper, Roberto Badagliacca, Rolf M F Berger, Margarita Brida, Jørn Carlsen, Andrew J S Coats, Pilar Escribano-Subias, Pisana Ferrari, Diogenes S Ferreira, Hossein Ardeschir Ghofrani, George Giannakoulas, David G Kiely, Eckhard Mayer, Gergely Meszaros, Blin Nagavci, Karen M Olsson, Joanna Pepke-Zaba, Jennifer K Quint, Göran Rådegran, Gerald Simonneau, Olivier Sitbon, Thomy Tonia, Mark Toshner, Jean Luc Vachiery, Anton Vonk Noordegraaf, Marion Delcroix, Stephan Rosenkranz, ESC/ERS Scientific Document Group, 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)., European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3618–3731.
dcterms.references	Korsholm K, Andersen A, Kirkfeldt RE, Hansen KN, Mellemkjær S, Nielsen-Kudsk JE. Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. Pulm Circ. 2015 Jun;5(2):364-9. doi: 10.1086/681270. PMID: 26064463; PMCID: PMC4449249.
dcterms.references	Mazzei JA, Cáneva JO, Khoury M, Melero MJ. Mortality due to idiopathic pulmonary hypertension in Argentina. Insuficiencia Cardiaca. 2015;10.
dcterms.references	Schwartz SS, Madsen N, Laursen HB, Hirsch R, Olsen MS. Incidence and Mortality of Adults With Pulmonary Hypertension and Congenital Heart Disease. Am J Cardiol. 2018 Jun 15;121(12):1610-1616. doi: 10.1016/j.amjcard.2018.02.051. Epub 2018 Mar 14. PMID: 29655882.
dcterms.references	Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest. 2011 Jun;139(6):1285-1293. doi: 10.1378/chest.10-1293. Epub 2010 Nov 11. PMID: 21071530.
dcterms.references	Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger CD, Frantz RP. Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERSBased Risk Assessment Strategies. Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14. PMID: 30772387.
dcterms.references	Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–223.
dcterms.references	Sun XG, Hansen JE, Oudiz RJ, et al. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol 2003; 41: 1028–1035.
dcterms.references	Melot C, Naeije R. Pulmonary vascular diseases. Compr Physiol 2011; 1: 593–619.
dcterms.references	Harbaum L, Fuge J, Kamp JC, et al. Blood carbon dioxide tension and risk in pulmonary arterial hypertension. Int J Cardiol 2020; 318: 131–137.
dcterms.references	Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192–1201
dcterms.references	Galderisi M, Cosyns B, Edvardsen T, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18: 1301–1310.
dcterms.references	Kovacs G, Avian A, Olschewski A, et al. Zero reference level for right heart catheterisation. Eur Respir J 2013; 42: 1586–1594.
dcterms.references	Chin KM, Rubin LJ, Channick R, et al. Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension: insights from the phase III GRIPHON study. Circulation 2019; 139: 2440–2450.
dcterms.references	Ward MP, Milledge JS, West J, eds. High-Altitude Medicine and Physiology. New York, Oxford University Press, 2000.
dcterms.references	MoudgilR,MichelakisED,ArcherSL.Hypoxicpulmonary vasoconstriction. J Appl Physiol 2005; 98: 390–403.
dcterms.references	.Durmowicz AG, Stenmark KR. Mechanisms of structural remodeling in chronic pulmonary hypertension.
dcterms.references	.Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, Maloney J, De Marco T, Ivy D, Thenappan T, Sager JS, Ryan JJ, Mazimba S, Hirsch R, Chakinala M, Shlobin O, Lammi M, Zwicke D, Robinson J, Benza RL, Klinger J, Grinnan D, Mathai S, Badesch D. Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. Pulm Circ. 2020 Nov 10;10(4):2045894020964342. doi: 10.1177/2045894020964342. Erratum in: Pulm Circ. 2022 Jul 01;12(3):e12112. PMID: 33240488; PMCID: PMC7675880.
dcterms.references	Khanna D, Zhao C, Saggar R, Mathai SC, Chung L, Coghlan JG, Shah M, Hartney J, McLaughlin V. Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. Arthritis Rheumatol. 2021 May;73(5):837-847. doi: 10.1002/art.41669. Epub 2021 Mar 29. PMID: 33538058; PMCID: PMC82518.
thesis.degree.discipline	Facultad de Medicina	es_CO
thesis.degree.level	Especialización en Neumología	es_CO
thesis.degree.name	Especialista en Neumología	es_CO